Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

682

HTML

8429

Figures (1-3)

417

Tables (1-2)

359

Sum=9887

Feb 7, 2011 (publication date) through Apr 19, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 7, 2011; 17(5): 547-556
Published online Feb 7, 2011. doi: 10.3748/wjg.v17.i5.547

Table 1 Clinical efficacy and marketing approval for anti-tumor necrosis factor-α agents

Drug name	Efficacy (% of induction of remission/% sustained remission)			Approved (FDA/Europe)
Drug name	Luminal CD	Fistulizing CD	UC	Luminal CD	Fistulizing CD	UC
Infliximab (Remicade^®)	33/45	55/36	38.8/23.1	Yes/Yes	Yes/Yes	Yes/Yes
Adalimumab (Humira^®)	36/36	No RCT	No RCT	Yes/Yes	No/No	No/No
Certolizumab (Cimzia^®)	35/48	No RCT	No RCT	Yes/No	No/No	No/No

CD: Crohn’s disease; UC: Ulcerative colitis; FDA: US food and drug administration; RCT: Randomized controlled trial.

Citation: Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17(5): 547-556
URL: https://www.wjgnet.com/1007-9327/full/v17/i5/547.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i5.547